Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027

黄斑変性症および糖尿病網膜症治療の世界市場予測

◆タイトル:Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027
◆商品コード:VGAIN7081157
◆調査・発行会社:visiongain
◆発行日:2017年7月
◆ページ数:196
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、黄斑変性症および糖尿病網膜症治療の世界市場について調査・分析し、黄斑変性症および糖尿病網膜症治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・黄斑変性症および糖尿病網膜症治療の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・黄斑変性症および糖尿病網膜症治療の世界市場:セグメント別市場分析
・黄斑変性症および糖尿病網膜症治療の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Macular Degeneration, Diabetic Retinopathy and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenues
Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 169-page report provides 80 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2017-2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2027 for the following submarkets:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2017 to 2027 at world level? Our study forecasts revenues of four prominent brands:
• Lucentis
• Eylea
• Avastin
• Visudyne

Discover how high revenues can go. See what’s happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 10 leading national markets from 2017-2027:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth
Our analysis forecasts that the world market for retinal drugs will reach $11.98bn in 2017. It will achieve strong revenue expansion from 2017 to 2027. Our report reveals how high sales will go over the next 10 years.

Research and development – assess innovation, trends and possibilities
There you can also investigate R&D, appraising technological, clinical and commercial possibilities.
In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:
• Combination therapies, including neovascularisation disrupters
• Angiogenesis inhibition by blocking pericyte recruitment
• Anti-inflammatory mechanisms (inc. corticosteroids)
• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
• Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:
• Oligonucleotides and siRNA therapy
• Anti-integrin oligopeptide treatment
• Complement factor inhibition and serotonin modifiers
• Angiotensin receptor blockers and converting enzyme inhibitors
• Biosimilars and other follow-on biologicals and next generation therapeutics
• Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA). Avoid missing out – get our report now.

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Main Questions Answered by This Analysis
1.4 Who Is This Study For?
1.5 Methods of Research and Analysis
1.6 Frequently Asked Questions (FAQs)
1.7 Some Associated Reports
1.8 About Visiongain

2. World AMD and Other Disease Market, 2016
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2027
2.8 Eylea Stood as the Leading Drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2016
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2016-2027
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2016-2027

4. Approved Products in the AMD and Other Retinal Diseases Market, 2016-2027
4.1 Will the Current Products Dominate the Market Through 2027?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2016
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis?
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2016-2027
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2016-2027
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2016-2027
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2016-2027
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013

5. Pipeline for Wet AMD Segment, 2016-2027
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/ Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.2.6 Biosmiliars of Lucentis: FYB201 & PF-582
5.2.7 TK001/sevacizumab (Jiangsu T-Mab Biopharma)‘s recombinant humanized anti-VEGF monoclonal antibody
5.2.8 Roche’s RG7716 (RO-6867461), an anti- VEGF A monoclonal antibody
5.2.9 Opthea’s OPT-302, a VEGFR inhibitor
5.2.10 Daiichi Sankyo’s DS7080, an angiogenesis inhibitor
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 Regeneron’s REGN910-3 (Nesvacumab + Aflibercept) and REGN910 (Nesvacumab)
5.3.5 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): Launched in China for wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for Wet AMD
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
5.7.9 Zybrestat (Mateon Therapeutics Oxigene, formerly OxiGENE): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Alcon’s LMG324 and LHA510 for wAMD
5.7.11 hI-con1 (Iconic Therapeutics), VII-IgGFc chimeric protein targeting tissue factor
5.7.12 Synthetic Biologics: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5.8.5 Gene Therapy (RGX-314) for Neovascular AMD
5.8.6 Stem cell therapy with Pfizer’s PF05206388
5.8.7 Diffusion Pharmaceuticals’ Palomid-529
5.8.8 MT-0814 (Mitsubishi Tanabe Pharma), CC chemokine receptor 3 antagonist for AMD
5.8.9 Undisclosed MoA of Boehringer Ingelheim’s BI 144807 for Wet AMD

6. Pipeline for Dry AMD Segment, 2016
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Disappointing results of Phase 2/3 trial
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine’s Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Neurotech’s Renexsus: Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Ophthotech’s Zimura for Geographic Atrophy
6.7.7 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2016
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Clearside Biomedical’s CLS-TA/ CLS1004
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.4.6 Kala Pharmaceuticals’ KPI-121
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 Jetrea (ThromboGenics /Novartis): Possibilities in DME?
7.5.5 SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for DME
7.5.6 Pan-90806 (PanOptica): Anti-VEGF Eyedrop
7.5.7 Teprotumumab (Horizon Pharma): an insulin-like growth factor-1 receptor antagonist
7.6 Undisclosed MoA of Boehringer Ingelheim’s BI 1026706 for DME

8. Regional Market Breakdown, 2016
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2017-2027
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and R&D Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges

10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

Associated Visiongain Reports
Glossary
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 2.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2016
Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2016
Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2016
Table 3.3 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
Table 3.4 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
Table 3.5 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
Table 3.6 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 3.7 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2016, 2021 and 2027
Table 4.1 Major Retinal Drugs Market Forecast: Revenue ($bn), CAGR (%) for 2016-2027
Table 4.10 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
Table 4.4 Lucentis: Revenue ($bn), AGR (%), 2012-2016
Table 4.5 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
Table 4.6 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.7 Eylea: Revenue ($bn), AGR (%), 2013-2016
Table 4.8 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.9 Avastin: Revenue ($bn), AGR (%), 2012-2014
Table 4.11 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
Table 5.1 Selected R&D Pipeline (Phase 3) for wAMD, 2016
Table 5.2 Selected R&D Pipeline (Phase 2 & 1/2) for wAMD, 2016
Table 5.3 Selected R&D Pipeline (Phase 1) for wAMD, 2016
Table 6.1 Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
Table 6.2 Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
Table 7.1 Selected R&D Pipeline (Phase 2 & 3) for Diabetic Retinopathy, 2016
Table 7.2 Selected R&D Pipeline (Phase 1 & !/2) for Diabetic Retinopathy, 2016
Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027 (continued)
Table 8.2 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 8.3 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 8.4 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 8.5 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 9.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2016
Table 9.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2016
Table 9.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2027

List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2016-2027
Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2016
Figure 2.3 Market Breakdown by Company: Market Share (%), 2016
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2016
Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2016
Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2016-2027
Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2016-2027
Figure 3.5 DR Segment Forecast: Revenue ($bn), 2016-2027
Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016-2027
Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016, 2021 and 2027
Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2021
Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2027
Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
Figure 4.3 Market Forecast by Product: Revenue ($bn), 2016-2027
Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2016, 2021 and 2027
Figure 4.5 Lucentis: Revenues Forecast ($bn), 2016-2027
Figure 4.6 Drivers and Restraints for Lucentis, 2016
Figure 4.7 Eylea Forecast: Revenue ($bn), 2016-2027
Figure 4.8 Drivers and Restraints for Eylea, 2016
Figure 4.9 Avastin Forecast: Revenue ($bn), 2016-2027
Figure 4.10 Drivers and Restraints for Avastin, 2016
Figure 4.11 Visudyne Forecast: Revenues ($bn), 2016-2027
Figure 8.1 Regional Breakdown: Revenue ($bn), 2016-2027
Figure 8.2 Regional Breakdown: Revenue ($bn), 2016, 2021 and 2027
Figure 8.3 Regional Market Share (%), 2016
Figure 8.4 Regional Market Share (%), 2021
Figure 8.5 Regional Market Share (%), 2027
Figure 8.6 US Market: Revenue ($bn), 2016-2027
Figure 8.7 Japan: Revenue ($bn), 2016-2027
Figure 8.8 EU5: Grouped Revenue ($bn), 2016-2027
Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2016-2027
Figure 8.10 EU5 Breakdown: Market Share (%), 2016
Figure 8.11 EU5 Breakdown: Market Share (%), 2021
Figure 8.12 EU5 Breakdown: Market Share (%), 2027
Figure 8.13 BRIC Nations Forecast: Grouped Revenue ($bn), 2016-2027
Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2016-2027
Figure 8.15 Market Share (%) within BRIC Group by Country, 2016
Figure 8.16 Market Share (%) within BRIC Group by Country, 2021
Figure 8.17 Market Share (%) within BRIC Group by Country, 2027

【レポートのキーワード】

黄斑変性症、糖尿病網膜症、治療薬

★調査レポート[黄斑変性症および糖尿病網膜症治療の世界市場予測] ( Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027 / VGAIN7081157) 販売に関する免責事項
[黄斑変性症および糖尿病網膜症治療の世界市場予測] ( Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027 / VGAIN7081157) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆